PT3463465T - Exossomas que compreendem polipéptidos terapêuticos - Google Patents
Exossomas que compreendem polipéptidos terapêuticosInfo
- Publication number
- PT3463465T PT3463465T PT177273257T PT17727325T PT3463465T PT 3463465 T PT3463465 T PT 3463465T PT 177273257 T PT177273257 T PT 177273257T PT 17727325 T PT17727325 T PT 17727325T PT 3463465 T PT3463465 T PT 3463465T
- Authority
- PT
- Portugal
- Prior art keywords
- exosomes
- therapeutic polypeptides
- polypeptides
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01021—Beta-glucosidase (3.2.1.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1609216.5A GB201609216D0 (en) | 2016-05-25 | 2016-05-25 | Exosomes comprising therapeutic polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3463465T true PT3463465T (pt) | 2020-11-04 |
Family
ID=56369954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT177273257T PT3463465T (pt) | 2016-05-25 | 2017-05-25 | Exossomas que compreendem polipéptidos terapêuticos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11534499B2 (pt) |
EP (2) | EP3463465B1 (pt) |
JP (2) | JP6855567B2 (pt) |
KR (1) | KR102253731B1 (pt) |
CN (2) | CN116103241A (pt) |
AU (1) | AU2017270932B2 (pt) |
BR (1) | BR112018074229A2 (pt) |
CA (1) | CA3024020C (pt) |
DK (1) | DK3463465T3 (pt) |
ES (1) | ES2836553T3 (pt) |
GB (1) | GB201609216D0 (pt) |
MX (1) | MX2018014509A (pt) |
PT (1) | PT3463465T (pt) |
RU (1) | RU2737732C2 (pt) |
SG (1) | SG11201810116VA (pt) |
WO (1) | WO2017203260A1 (pt) |
ZA (1) | ZA201807945B (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201609216D0 (en) | 2016-05-25 | 2016-07-06 | Evox Therapeutics And Isis Innovation Ltd | Exosomes comprising therapeutic polypeptides |
JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
GB2568255A (en) * | 2017-11-08 | 2019-05-15 | Evox Therapeutics Ltd | Exosomes comprising RNA therapeutics |
EP3781131A4 (en) * | 2018-04-19 | 2022-06-01 | Board of Regents, The University of Texas System | THERAPEUTIC MODULATION OF TUMOR SUPPRESSORS USING EXOSOMES |
CN108753806A (zh) * | 2018-06-20 | 2018-11-06 | 中国人民解放军第四军医大学 | 增强目标rna装载入外泌体的融合蛋白的表达载体及其构建方法和应用 |
CN108753822A (zh) * | 2018-06-20 | 2018-11-06 | 中国人民解放军第四军医大学 | 递送融合型rna结合蛋白的表达载体及其制备方法和应用 |
CN109293745A (zh) * | 2018-09-04 | 2019-02-01 | 暨南大学 | 一种运载蛋白、重组表达载体、外泌体及制备方法与应用 |
CN109321596B (zh) * | 2018-09-05 | 2021-12-17 | 暨南大学 | 一种包载蛋白的外泌体的制备方法与应用 |
CN109234237B (zh) * | 2018-09-30 | 2020-08-07 | 中国人民解放军第四军医大学 | 一种装载ABCA1 mRNA的外泌体及其构建方法和应用 |
JP2022512988A (ja) * | 2018-11-16 | 2022-02-07 | エヴォックス・セラピューティクス・リミテッド | 尿素サイクルタンパク質および核酸を補充するための細胞外小胞 |
WO2020152298A1 (en) * | 2019-01-24 | 2020-07-30 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Method for producing enzymes |
JP2022519275A (ja) * | 2019-02-04 | 2022-03-22 | コディアック バイオサイエンシーズ, インコーポレイテッド | エクソソーム操作のための膜タンパク質足場 |
US20240024220A1 (en) * | 2019-05-11 | 2024-01-25 | Youngsuk Yi | Neurotoxin compositions and methods |
CN114269360A (zh) * | 2019-06-21 | 2022-04-01 | 恩特莱科索生物治疗公司 | 用于治疗递送的平台、组合物和方法 |
KR102125567B1 (ko) * | 2019-07-02 | 2020-06-22 | 한양대학교 에리카산학협력단 | 식물 엑소좀의 대량 생산 방법 |
WO2021039884A1 (ja) * | 2019-08-28 | 2021-03-04 | 国立研究開発法人理化学研究所 | 細胞膜透過性ベシクル |
CN110954703A (zh) * | 2019-12-27 | 2020-04-03 | 杭州迪相实业有限公司 | 一种同时检测外泌体内蛋白和rna、外泌体膜蛋白的方法 |
WO2021159016A1 (en) | 2020-02-05 | 2021-08-12 | Diadem Biotherapeutics Inc. | Artificial synapses |
US20230211010A1 (en) * | 2020-02-10 | 2023-07-06 | Exostemtech Co., Ltd. | Exosome comprising photocleavable protein, and use thereof |
CN115484990A (zh) | 2020-03-12 | 2022-12-16 | 基础科学研究院 | 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法 |
WO2021223659A1 (en) * | 2020-05-06 | 2021-11-11 | Nanjing Iaso Biotherapeutics Co., Ltd. | Extracellular vesicles targeting cancer cells and uses thereof |
CN111569077B (zh) * | 2020-05-29 | 2021-10-26 | 南方医科大学 | Flot2抑制剂在抑制破骨细胞形成和/或破骨活性中的应用 |
RU2766707C1 (ru) * | 2020-11-13 | 2022-03-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В.Ломоносова» (МГУ) | Средство для лечения фиброза тканей на основе компонентов секретома мезенхимных стромальных клеток, способ получения и применения средства |
CN112773775B (zh) * | 2021-01-13 | 2022-12-20 | 广东药科大学 | 一种负载去甲斑蝥素外泌体的制备方法及其应用 |
WO2022158836A1 (ko) * | 2021-01-21 | 2022-07-28 | 주식회사 엑소코바이오 | 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도 |
WO2022215078A1 (en) * | 2021-04-07 | 2022-10-13 | Ramot At Tel-Aviv University Ltd. | Modified cannabinoids and uses thereof |
EP4320234A2 (en) | 2021-04-07 | 2024-02-14 | Astrazeneca AB | Compositions and methods for site-specific modification |
JP2024514671A (ja) * | 2021-04-22 | 2024-04-02 | オハイオ・ステイト・イノベーション・ファウンデーション | 腫瘍関連マクロファージを標的とするためのナノキャリア |
GB202107182D0 (en) * | 2021-05-19 | 2021-06-30 | Evox Therapeutics Ltd | Nanoparticle delivery system for production of engineered extracellular vesicles |
US20240035906A1 (en) | 2021-06-16 | 2024-02-01 | Nsk Ltd. | Load estimating device for rolling bearing, control device for mechanical device provided with rolling bearing, load estimating method, and program |
WO2023001894A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
WO2023058691A1 (ja) | 2021-10-07 | 2023-04-13 | 合同会社H.U.グループ中央研究所 | 構築物 |
IL313161A (en) | 2021-12-03 | 2024-07-01 | Harvard College | Preparations and methods for effective administration to the body |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
GB202211033D0 (en) * | 2022-07-28 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Purification process |
WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
CN116803424B (zh) * | 2023-08-24 | 2023-11-28 | 上海懿贝瑞生物医药科技有限公司 | Slc17a5基因抑制剂及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834247A (en) * | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
US5935822A (en) | 1995-03-21 | 1999-08-10 | The Regents Of The University Of Colorado | Product and process for membrane and soluble polypeptide segregation |
GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
MX2010002002A (es) | 2007-08-20 | 2010-03-11 | Oncotherapy Science Inc | Peptido foxm1 y agente medicinal que lo contiene. |
ES2632123T3 (es) | 2007-08-20 | 2017-09-11 | Oncotherapy Science, Inc. | Péptido CDH3 y agente medicinal que comprende el mismo |
EP2127640A1 (en) | 2008-05-27 | 2009-12-02 | Koninklijke Philips Electronics N.V. | Azide modified proteins |
GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
CN103205435A (zh) | 2013-04-11 | 2013-07-17 | 浙江大学 | 利用内含肽系统大肠杆菌表达乳铁蛋白改良肽lf-6的方法 |
US11274139B2 (en) | 2013-04-12 | 2022-03-15 | Evox Therapeutics Ltd | Therapeutic delivery vesicles |
WO2014200659A1 (en) | 2013-06-11 | 2014-12-18 | Clontech Laboratories, Inc. | Protein enriched microvesicles and methods of making and using the same |
WO2015002956A1 (en) | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
CA2935587A1 (en) | 2014-02-11 | 2015-08-20 | The Governors Of The University Of Alberta | Genetically encoded photocleavable proteins |
WO2015138878A1 (en) | 2014-03-13 | 2015-09-17 | Research Institute At Nationwide Children's Hospital, Inc. | Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes |
WO2016077639A2 (en) * | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
WO2016178532A1 (ko) * | 2015-05-04 | 2016-11-10 | 한국과학기술원 | 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법 |
EP3445378A1 (en) * | 2016-04-22 | 2019-02-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and vaccine compositions for the treatment of b-cell malignancies |
GB201609216D0 (en) | 2016-05-25 | 2016-07-06 | Evox Therapeutics And Isis Innovation Ltd | Exosomes comprising therapeutic polypeptides |
-
2016
- 2016-05-25 GB GBGB1609216.5A patent/GB201609216D0/en not_active Ceased
-
2017
- 2017-05-25 EP EP17727325.7A patent/EP3463465B1/en active Active
- 2017-05-25 DK DK17727325.7T patent/DK3463465T3/da active
- 2017-05-25 BR BR112018074229-5A patent/BR112018074229A2/pt not_active Application Discontinuation
- 2017-05-25 AU AU2017270932A patent/AU2017270932B2/en active Active
- 2017-05-25 CN CN202211545146.5A patent/CN116103241A/zh active Pending
- 2017-05-25 ES ES17727325T patent/ES2836553T3/es active Active
- 2017-05-25 RU RU2018145738A patent/RU2737732C2/ru active
- 2017-05-25 MX MX2018014509A patent/MX2018014509A/es unknown
- 2017-05-25 CA CA3024020A patent/CA3024020C/en active Active
- 2017-05-25 KR KR1020187037527A patent/KR102253731B1/ko active IP Right Grant
- 2017-05-25 WO PCT/GB2017/051479 patent/WO2017203260A1/en unknown
- 2017-05-25 SG SG11201810116VA patent/SG11201810116VA/en unknown
- 2017-05-25 US US16/304,580 patent/US11534499B2/en active Active
- 2017-05-25 PT PT177273257T patent/PT3463465T/pt unknown
- 2017-05-25 JP JP2019514870A patent/JP6855567B2/ja active Active
- 2017-05-25 CN CN201780046456.3A patent/CN109715211B/zh active Active
- 2017-05-25 EP EP20201528.5A patent/EP3782646A1/en active Pending
-
2018
- 2018-11-23 ZA ZA2018/07945A patent/ZA201807945B/en unknown
-
2021
- 2021-03-16 JP JP2021042290A patent/JP7483648B2/ja active Active
-
2022
- 2022-11-21 US US18/057,359 patent/US20230201370A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109715211A (zh) | 2019-05-03 |
AU2017270932A1 (en) | 2018-12-20 |
WO2017203260A1 (en) | 2017-11-30 |
EP3463465B1 (en) | 2020-10-14 |
CN109715211B (zh) | 2022-12-20 |
ES2836553T3 (es) | 2021-06-25 |
DK3463465T3 (da) | 2020-12-14 |
AU2017270932B2 (en) | 2021-04-29 |
US11534499B2 (en) | 2022-12-27 |
US20230201370A1 (en) | 2023-06-29 |
EP3782646A1 (en) | 2021-02-24 |
RU2018145738A3 (pt) | 2020-09-08 |
JP2019520852A (ja) | 2019-07-25 |
GB201609216D0 (en) | 2016-07-06 |
CN116103241A (zh) | 2023-05-12 |
MX2018014509A (es) | 2019-06-06 |
RU2018145738A (ru) | 2020-06-25 |
KR102253731B1 (ko) | 2021-05-24 |
RU2737732C2 (ru) | 2020-12-02 |
US20190167810A1 (en) | 2019-06-06 |
EP3463465A1 (en) | 2019-04-10 |
CA3024020A1 (en) | 2017-11-30 |
CA3024020C (en) | 2022-03-08 |
JP7483648B2 (ja) | 2024-05-15 |
KR20190011279A (ko) | 2019-02-01 |
ZA201807945B (en) | 2020-05-27 |
JP2021100416A (ja) | 2021-07-08 |
JP6855567B2 (ja) | 2021-04-07 |
SG11201810116VA (en) | 2018-12-28 |
BR112018074229A2 (pt) | 2019-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201807945B (en) | Exosomes comprising therapeutic polypeptides | |
ZA201802261B (en) | Polypeptides | |
HK1250041A1 (zh) | 多肽 | |
IL265463A (en) | Therapeutic peptides related to mots-c | |
ZA201704366B (en) | Il-17a-binding polypeptides | |
HK1250040A1 (zh) | 多肽 | |
GB201609597D0 (en) | Therapy | |
GB201502412D0 (en) | Therapeutic use | |
GB201608797D0 (en) | Therapeutic use | |
ZA201902689B (en) | Therapeutic protein | |
GB201604318D0 (en) | Combination therapy | |
GB201604316D0 (en) | Combination therapy | |
GB201609735D0 (en) | Combination therapy | |
GB201603653D0 (en) | Combination Therapy | |
GB201506786D0 (en) | Therapeutic use | |
HK1251873A1 (zh) | 治療性肽 | |
IL268046A (en) | Therapeutic peptides | |
PL3562548T3 (pl) | Urządzenie terapeutyczne | |
GB201616715D0 (en) | Therapeutic protein | |
GB201618477D0 (en) | Therapy | |
GB201617451D0 (en) | Polypeptides for use in therapy | |
GB201615923D0 (en) | Macrophage-based therapy | |
GB201609721D0 (en) | Cobination therapy | |
GB201609312D0 (en) | Therapy | |
GB201609322D0 (en) | Therapy |